Kaleido Biosciences Inc (KLDO)
OTHER OTC:KLDO
KLDO Stock Chart & Stats
$0.20
<$0.01(100.00%)
At close: 4:00 PM EST
$0.20
<$0.01(100.00%)
Day’s Range― - ―
52-Week Range$0.01 - $0.35
Previous CloseN/A
Volume300.00
Average Volume (3M)385.00
Market Cap
$4.26K
Enterprise Value-$16.78M
Total Cash (Recent Filing)$38.47M
Total Debt (Recent Filing)$21.69M
Price to Earnings (P/E)―
Beta331.81
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.71
Shares Outstanding42,622,560
10 Day Avg. Volume409
30 Day Avg. Volume385
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)9.43
Price to Sales (P/S)90.62
P/FCF Ratio-1.28
Enterprise Value/Market Cap-3.94K
Enterprise Value/Revenue-15.20
Enterprise Value/Gross Profit-15.20
Enterprise Value/Ebitda0.20
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
KLDO FAQ
What was Kaleido Biosciences Inc’s price range in the past 12 months?
Kaleido Biosciences Inc lowest stock price was $0.01 and its highest was $0.35 in the past 12 months.
What is Kaleido Biosciences Inc’s market cap?
Kaleido Biosciences Inc’s market cap is $4.26K.
When is Kaleido Biosciences Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Kaleido Biosciences Inc’s earnings last quarter?
Currently, no data Available
Is Kaleido Biosciences Inc overvalued?
According to Wall Street analysts Kaleido Biosciences Inc’s price is currently Overvalued.
Does Kaleido Biosciences Inc pay dividends?
Kaleido Biosciences Inc does not currently pay dividends.
What is Kaleido Biosciences Inc’s EPS estimate?
Kaleido Biosciences Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kaleido Biosciences Inc have?
Kaleido Biosciences Inc has 42,622,560 shares outstanding.
What happened to Kaleido Biosciences Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Kaleido Biosciences Inc?
Currently, no hedge funds are holding shares in KLDO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kaleido Biosciences Inc
Kaleido Biosciences, Inc. is a clinical-stage healthcare firm dedicated to pioneering microbiome metabolic therapies. Its pipeline includes specific drug candidates such as KB195 for urea cycle disorders, KB295 targeting ulcerative colitis, KB174 aimed at hepatic encephalopathy, and KB109 for COVID-19. The company is also advancing programs in other significant therapeutic areas, including multi-drug resistant infections, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and various inflammatory bowel conditions. Kaleido maintains strategic collaborations with Institute Gustave Roussy, Washington University, and Janssen. Established in 2015, its headquarters are situated in Lexington, Massachusetts.
Technical Analysis
Ownership Overview
―
Insiders
<0.01% Other Institutional Investors
99.97% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---